Effects of Jianpi Xiaoying Formula on Th1 and Th17 in mice of Hashimoto's thyroiditis model

LIU Mengran; TIAN Shengda; ZHANG Hongli; LI Xiaohua

doi:10.16306/j.1008-861x.2024.02.007

您当前的位置：

首页 >

文章列表页 >

Effects of Jianpi Xiaoying Formula on Th1 and Th17 in mice of Hashimoto's thyroiditis model

Special column on anti-inflammatory of traditional Chinese medicine | 更新时间：2024-04-15

- Effects of Jianpi Xiaoying Formula on Th1 and Th17 in mice of Hashimoto's thyroiditis model
- Academic Journal of Shanghai University of Traditional Chinese Medicine Vol. 38, Issue 2, Pages: 43-51(2024)
- 作者机构：
  
  上海中医药大学附属第七人民医院内分泌科（上海　200137）
- 作者简介：
- 基金信息：
- DOI：10.16306/j.1008-861x.2024.02.007
  CLC：
- Published：25 March 2024，
  
  Received：05 September 2023，
  
  Revised：18 December 2023，
扫描看全文
刘梦冉,田胜达,张宏利等.健脾消瘿方对桥本甲状腺炎模型小鼠Th1、Th17的影响[J].上海中医药大学学报,2024,38(02):43-51.

LIU Mengran,TIAN Shengda,ZHANG Hongli,et al.Effects of Jianpi Xiaoying Formula on Th1 and Th17 in mice of Hashimoto's thyroiditis model[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2024,38(02):43-51.
刘梦冉,田胜达,张宏利等.健脾消瘿方对桥本甲状腺炎模型小鼠Th1、Th17的影响[J].上海中医药大学学报,2024,38(02):43-51. DOI： 10.16306/j.1008-861x.2024.02.007.

LIU Mengran,TIAN Shengda,ZHANG Hongli,et al.Effects of Jianpi Xiaoying Formula on Th1 and Th17 in mice of Hashimoto's thyroiditis model[J].Academic Journal of Shanghai University of Traditional Chinese Medicine,2024,38(02):43-51. DOI： 10.16306/j.1008-861x.2024.02.007.

摘要

目的

探讨健脾消瘿方是否通过调控辅助性T细胞（Th）比例改善桥本甲状腺炎（HT）。

方法

将40只雌性CBA/J小鼠随机分为5组：正常对照组、模型对照组及健脾消瘿方低、中、高剂量组，每组8只。除正常对照组外，其他小鼠采用皮下注射猪甲状腺球蛋白联合高碘水喂养诱导HT模型。造模结束后，正常对照组与模型对照组小鼠每天给予0.5 mL饮用水灌胃，健脾消瘿方低、中、高剂量组小鼠每天给予健脾消瘿方颗粒剂水溶液（剂量分别为8.632 g/kg、17.264 g/kg、34. 528 g/kg）灌胃，连续6周。干预结束后，采用酶联免疫吸附试验（ELISA）检测小鼠血清甲状腺过氧化物酶抗体（TPOAb）、甲状腺球蛋白抗体（TGAb）、游离三碘甲状腺原氨酸（FT3）、游离甲状腺素（FT4）、促甲状腺素（TSH）水平；采用流式细胞术检测小鼠外周血Th1、Th2、Th17、调节性T细胞（Treg）比例；采用实时荧光定量PCR检测肿瘤坏死因子-α（

TNF

）、γ干扰素（

IFN

）、白介素-17（

）、

bet

、

RORγ

基因表达；采用Western blot法检测脾脏组织T-bet、RORγ-t蛋白表达；苏木素-伊红（HE）染色观察甲状腺组织病理形态学变化。

结果

①与模型对照组相比，健脾消瘿方高剂量组小鼠血清TPOAb水平显著降低（

0.05），健脾消瘿方低、高剂量组小鼠的TGAb水平亦显著降低（

0.05）。②与模型对照组相比，健脾消瘿方高剂量组小鼠血清FT3、FT4水平明显上升（

0.05）。③健脾消瘿方可改善HT模型小鼠的甲状腺滤泡结构和滤泡胶质，使滤泡形态趋于规则，减轻甲状腺滤泡间淋巴细胞及浆细胞的浸润程度。④与模型对照组相比，健脾消瘿方低、中、高剂量组小鼠的外周血Th1比例均显著下降（

0.05），健脾消瘿方低、高剂量组小鼠的Th17比例亦显著降低（

0.05）。⑤与模型对照组相比，健脾消瘿方低、中、高剂量组小鼠的脾脏组织

bet

、

RORγ

基因相对表达量明显下降（

0.05），健脾消瘿方高剂量组的T-bet、RORγ-t蛋白表达显著下降（

0.05），健脾消瘿方中剂量组的T-bet蛋白表达显著下降（

0.05）。⑥与模型对照组相比，健脾消瘿方各剂量组小鼠的

TNF

、

IFN

、

基因相对表达量均明显降低（

0.05）。

结论

健脾消瘿方能通过下调Th1、Th17的转录分化及其相关炎症因子的分泌，抑制炎症反应，从而改善HT。

Abstract

Objective： To investigate whether Jianpi Xiaoying Formula improving Hashimoto's thyroiditis （HT） by regulating the proportion of helper T cells （Th）.

Methods

Forty female CBA/J mice were randomly divided into five groups： the normal control group， model control group， and the low， medium and high dose groups of Jianpi Xiaoying Formula， eight mice in each group. Except for the normal control group， the HT model was induced by subcutaneous injection of porcine thyroglobulin combined with iodized water feeding in mice of other groups. At the end of modeling， the mice in the normal control group and model control group were given 0.5 mL of drinking water by gavage every day， and the mice in the low， medium and high dose groups of Jianpi Xiaoying Formula were given aqueous solution of Jianpi Xiaoying Formula granules （with the doses of 8.632 g/kg， 17.264 g/kg and 34.528 g/kg respectively） by gavage every day， for consecutive 6 weeks. At the end of intervention， the levels of serum thyroid peroxidase antibody （TPOAb）， thyroglobulin antibody （TGAb）， free triiodothyronine （FT3）， free thyroxine （FT4） and thyrotropin （TSH） in mice were detected by enzyme-linked immunosorbent assay （ELISA）； the proportions of Th1， Th2， Th17 and regulatory T cell （Treg） in peripheral blood of mice were detected by flow cytometry； the gene expressions of tumor necrosis factor-α （

TNF

），

interferon （

IFN

）， interleukin-17 （

），

bet

and

RORγ

‑

were detected by real-time fluorescence quantitative PCR； the protein expressions of T-bet and RORγ-t in spleen tissues were detected by Western blot； the pathological and morphological changes of thyroid tissue were observed by hematoxylin-eosin （HE） staining.

Results

①Compared with the model control group， the level of serum TPOAb of mice in the high dose group of Jianpi Xiaoying Formula was significantly decreased （

0.05）， and the level of TGAb of mice in the low and high dose groups of Jianpi Xiaoying Formula was also significantly decreased （

0.05）. ②Compared with the model control group， the serum FT3 and FT4 levels of mice in the high dose group of Jianpi Xiaoying Formula were significantly increased （

0.05）. ③Jianpi Xiaoying Formula can improve the structure and colloid of thyroid follicles， make the follicle morphology regular， and reduce the degree of infiltration of inter-follicular lymphocytes and plasma cells in thyroid of the HT model mice. ④Compared with the model control group， the Th1 ratio in peripheral blood of mice in the low， medium and high dose groups of Jianpi Xiaoying Formula was significantly decreased （

0.05）， and the Th17 ratio of mice in the low and high dose groups of Jianpi Xiaoying Formula was also significantly decreased （

0.05）. ⑤Compared with the model control group， the relative expressions of

bet

and

RORγ

genes in the spleen tissues of mice in the low， medium and high dose groups of Jianpi Xiaoying Formula were significantly decreased （

0.05）， the protein expressions of T-bet and RORγ-t in the high dose group of Jianpi Xiaoying Formula were significantly decreased （

0.05）， and the protein expression of T-bet in the medium dose group of Jianpi Xiaoying Formula was significantly decreased （

0.05）. ⑥Compared with the model control group， the relative expressions of

TNF

，

IFN

and

genes of mice in each dose groups of Jianpi Xiaoying Formula were significantly decreased （

0.05）.

Conclusion

Jianpi Xiaoying Formula can inhibit the inflammatory response by down-regulating the transcription and differentiation of Th1 and Th17 and the secretion of their related inflammatory factors， thus improve HT.

关键词

桥本甲状腺炎健脾消瘿方辅助性T细胞1辅助性T细胞17

Keywords

Hashimoto's thyroiditisJianpi Xiaoying Formulahelper T cell 1helper T cell 17

references

RALLI M， ANGELETTI D， FIORE M， et al. Hashimoto's thyroiditis： An update on pathogenic mechanisms， diagnostic protocols， therapeutic strategies， and potential malignant transformation［J］. Autoimmun Rev， 2020， 19（10）： 102649.

ANTONELLI A， FERRARI S M， CORRADO A， et al. Autoimmune thyroid disorders［J］. Autoimmun Rev， 2015， 14（2）： 174-180.

JANYGA S， MAREK B， KAJDANIUK D， et al. CD4+ cells in autoimmune thyroid disease［J］. Endokrynol Pol， 2021， 72（5）： 572-583.

MATIA-GARCIA I， VADILLO E， PELAYO R， et al. Th1/Th2 Balance in Young Subjects： Relationship with Cytokine Levels and Metabolic Profile［J］. J Inflamm Res， 2021， 14： 6587-6600.

LUTY J， RUCKEMANN-DZIURDZIŃSKA K， WITKOWSKI J M， et al. Immunological aspects of autoimmune thyroid disease—Complex interplay between cells and cytokines［J］. Cytokine， 2019， 116： 128-133.

WANG Y， FANG S， ZHOU H. Pathogenic role of Th17 cells in autoimmune thyroid disease and their underlying mechanisms［J］. Best Pract Res Clin Endocrinol Metab， 2023， 37（2）： 101743.

ZHANG W， LIU X， ZHU Y， et al. Transcriptional and posttranslational regulation of Th17/Treg balance in health and disease［J］. Eur J Immunol， 2021， 51（9）： 2137-2150.

PYZIK A， GRYWALSKA E， MATYJASZEK-MATUSZEK B， et al. Immune disorders in Hashimoto's thyroiditis： what do we know so far？［J］. J Immunol Res， 2015， 2015： 979167.

RAMOS-LEVÍ A M， MARAZUELA M. Pathogenesis of thyroid autoimmune disease： the role of cellular mechanisms［J］. Endocrinol Nutr， 2016， 63（8）： 421-429.

FASCHING P， STRADNER M， GRANINGER W， et al. Therapeutic Potential of Targeting the Th17/Treg Axis in Autoimmune Disorders［J］. Molecules， 2017， 22（1）： 134.

马燕云，唐红，杨华，等. 健脾消瘿汤治疗育龄期女性桥本甲状腺炎的临床研究［J］. 世界临床药物， 2022， 43（6）： 720-725.

MA Y Y， TANG H， YANG H， et al. Clinical study on Jianpi Xiaoying Decoction in the treatment of women of childbearing age with Hashimoto thyroiditis［J］. World Clinical Drug， 2022， 43（6）： 720-725.

汤家铭，陈民利. 医学实验动物学［M］. 北京：中国中医药出版社， 2012： 209-211.

TANG J M， CHEN M L. Medical Experimental Zoology［M］. Beijing： China Press of Traditional Chinese Medicine， 2012： 209-211.

钱晨宏，蒋烈浩，郑国湾，等. 中医药治疗桥本甲状腺炎现状与进展［J］. 浙江中西医结合杂志， 2021， 31（3）： 287-289.

QIAN C H， JIANG L H， ZHENG G W， et al. Status and progress of traditional Chinese medicine in treatment of Hashimoto thyroiditis［J］. Zhejiang Journal of Integrated Traditional Chinese and Western Medicine， 2021， 31（3）： 287-289.

王迪，梁伟娟，许雷鸣，等. 桥本甲状腺炎西药治疗进展［J］. 医学综述， 2021， 27（22）： 4501-4505.

WANG D， LIANG W J， XU L M， et al. Progress of Western Medicine in Treatment of Hashimoto Thyroiditis［J］. Medical Recapitulate， 2021， 27（22）： 4501-4505.

王苹. 桥本甲状腺炎的病因和治疗研究进展［J］. 医学理论与实践， 2022， 35（15）： 2556-2558.

WANG P. Progress in the etiology and treatment of Hashimoto thyroiditis［J］. The Journal of Medical Theory and Practice， 2022， 35（15）： 2556-2558.

韩静，刘守尧，夏仲元. 中医药干预桥本氏甲状腺炎作用机制的实验研究进展［J］. 中华中医药杂志， 2019， 34（9）： 4207-4209.

HAN J， LIU S Y， XIA Z Y. Experimental research progress on the intervention mechanism of TCM on Hashimoto's thyroiditis［J］. China Journal of Traditional Chinese Medicine and Pharmacy， 2019， 34（9）： 4207-4209.

盛阳，吴深涛. 吴深涛从“火郁发之”论治桥本甲状腺炎［J］. 中国中医药信息杂志， 2013， 20（9）： 88-89.

SHENG Y， WU S T. Wu Shentao's treatment of Hashimoto thyroiditis from “Huo Yu Fa Zhi”［J］. Chinese Journal of Information on Traditional Chinese Medicine， 2013， 20（9）： 88-89.

付佳闻，李晓华，李虹，等. 唐红教授治疗桥本氏甲状腺炎经验［J］. 福建中医药， 2020， 51（5）： 50-51.

FU J W， LI X H， LI H， et al. Professor Tang Hong's experience in treating Hashimoto's thyroiditis［J］. Fujian Journal of Traditional Chinese Medicine， 2020， 51（5）： 50-51.

陈秋野，周兰，马燕云，等. 健脾消瘿汤对脾气亏虚型桥本甲状腺炎患者的临床疗效［J］. 中成药， 2019， 41（9）： 2102-2106.

CHEN Q Y， ZHOU L， MA Y Y， et al. Clinical effects of Jianpi Xiaoying Decoction on patients with Hashimoto's thyroiditis due to Spleen-Qi Deficiency［J］. Chinese Traditional Patent Medicine， 2019， 41（9）： 2102-2106.

张雪琪，张帆，滕卫平. 辅助性T细胞17介导桥本甲状腺炎发病机制的研究现状［J］. 中华内分泌代谢杂志， 2022， 38（11）： 1001-1005.

ZHANG X Q， ZHANG F， TENG W P. Research advance in Hashimoto thyroiditis mediated by T helper cell 17［J］. Chinese Journal of Endocrinology and Metabolism， 2022， 38（11）： 1001-1005.

WANG S， BAIDOO S E， LIU Y， et al. T cell-derived leptin contributes to increased frequency of T helper type 17 cells in female patients with Hashimoto's thyroiditis［J］. Clin Exp Immunol， 2013， 171（1）： 63-68.

LI D， CAI W， GU R， et al. Th17 cell plays a role in the pathogenesis of Hashimoto's thyroiditis in patients［J］. Clin Immunol， 2013， 149（3）： 411-420.

更多指标>

Views

下载量

CSCD

CNKI被引量

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰